NewsBenzingaDaxor anuncia que nuevos estudios clínicos validan la tecnología BVA en poblaciones de insuficiencia cardíaca de alta gravedad para mejorar la atención en la Reunión Científica Anual HFSA 2026 Daxor anuncia que nuevos estudios clínicos validan la tecnología BVA en poblaciones de insuficiencia cardíaca de alta gravedad para mejorar la atención en la Reunión Científica Anual HFSA 2026 Benzinga 2026.10.14 12:08 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181 Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $870 Dow Warns High Interest Rates and Weak Consumer Confidence Are Hurting Housing Demand Evercore ISI Group Maintains Outperform on Knight-Swift, Raises Price Target to $79 Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75 Stock of the Day: Where is the Bottom for AT&T?
Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181
Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75
